Baarsma, M. E.
Vrijlandt, A.
Ursinus, J.
Zaaijer, H. L.
Jurriaans, S.
van Dam, A. P.
Hovius, J. W.
Funding for this research was provided by:
ITK Diagnostics
ZEUS Scientific
European Regional Development Fund
Article History
Received: 6 September 2021
Accepted: 25 October 2021
First Online: 22 November 2021
Declarations
:
: This project was submitted to the Medical Ethics Committee of Amsterdam UMC, which found it to be outside the scope of the Dutch Medical Research Involving Human Subjects Act (MEC decision W20_455).
: As this study used only de-identified leftover patient materials, informed consent from patients was not required. Healthy blood donors consented specifically to their materials being used for scientific purposes.
: Not applicable.
: None of the authors have received any personal financial compensation from ZEUS Scientific or any of the other assays’ manufacturers. MEB and JWH have in the past collaborated with Bio-Rad Laboratories (Hercules, CA, USA), QIAGEN (Germantown, MD, USA), Oxford Immunotec (Oxford, UK), Invitalabs (Neuss, Germany) and AID (Strassberg, Germany) on unrelated projects on LB diagnostics. They have not received any personal financial compensation from any of the aforementioned companies. MEB, APvD and JWH collaborate with Pfizer (New York City, NY, USA) on unrelated projects on LD. They have not received any personal financial compensation from Pfizer or any of the other companies for these projects. The other authors report no potential conflicts of interest.